However, this observation appears to be controversial, as targeting B cells with Rituximab led to a better outcome in cHL patients; moreover, B cells may trigger Hodgkin and Reed-Sternberg cell (HRS) growth through the expression of CD30L and CD40L [35]. This evidence concerns the gene CD40LG and classic Hodgkin lymphoma.